Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • The Inflation Reduction Act and What it Means for Methane Venting in the Natural Gas Industry
    The Inflation Reduction Act and What it Means for Methane Venting in the Natural Gas Industry World News
  • What do Russians say on the street?
    What do Russians say on the street? World News
  • WHFF.TV Sponsors Restoration of Black and Hispanic Families
    WHFF.TV Sponsors Restoration of Black and Hispanic Families World News
  • NATIONAL SPACE SOCIETY PRAISES FIFTH TEST FLIGHT OF SPACEX’S STARSHIP
    NATIONAL SPACE SOCIETY PRAISES FIFTH TEST FLIGHT OF SPACEX’S STARSHIP World News
  • War Day 240: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 240: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • HCSS Adds Julie Spurlin as Chief Human Resources Officer
    HCSS Adds Julie Spurlin as Chief Human Resources Officer Business
  • War Day 104: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 104: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Digitunity Report Identifies Need for Audio Enhancement
    Digitunity Report Identifies Need for Audio Enhancement Business
USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases

USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases

Posted on January 8, 2024 By NewsEditor

CLEVELAND, OH, UNITED STATES, January 8, 2024 /EINPresswire.com/ — NovelMed, a clinical-stage biopharmaceutical company with expertise in inflammatory and complement-related diseases, is pleased to announce that the United States Adopted Name (USAN) Council has officially assigned the generic name “Ruxoprubart (Ruk”soe proo’ bart)” to its monoclonal antibody candidate, NM8074, marking a significant milestone in the drug development process. Currently in Phase II trial for Paroxysmal Nocturnal Hemoglobinuria (PNH), a hemolytic disease, Ruxoprubart (NM8074) represents a significant breakthrough.

The USAN Council has approved the nonproprietary name “Ruxoprubart” (pronounced Ruk” soe proo’ bart) for NM8074, designating it as a first-in-class Alternative Pathway selective investigational monoclonal antibody. Administered through the USAN Program, a renowned organization for assigning distinct names to identify pharmaceutically active substances, the name Ruxoprubart reflects a novel nomenclature system for monoclonal antibodies, rooted in antibody type and mechanism of action.

Dr. Rekha Bansal, Chief Executive Officer of NovelMed, expressed, “The assignment of the nonproprietary name to NM8074 represents a significant milestone as we advance this potential PNH treatment towards study completion and regulatory filings. This allows us to establish a well-recognized name for future publications, labeling, and marketing materials.” Committed to scientific exploration, NovelMed continues to explore how its leading drug could address unmet needs in the field of PNH. Ruxoprubart, a potent and highly selective investigational drug candidate, targets the complement protein Bb, playing a crucial role in benefiting several complement-mediated diseases.

ABOUT RUXOPRUBART −−−

The USAN Council has officially designated Ruxoprubart as the generic name for NM8074. Distinguishing itself by exhibiting no affinity for Factor B, Ruxoprubart selectively binds to protein Bb. This humanized anti-Bb monoclonal antibody serves as a potent inhibitor of the Alternative Pathway.

Phase I Clinical Trial findings in healthy subjects have affirmed the safety and well-tolerance of NM8074. In all cohorts, complete inhibition of the Alternative Pathway (AP) was attained, with the duration of AP inhibition exhibiting a dose-dependent pattern. With the successful completion of the phase I trial in healthy volunteers, Ruxoprubart has advanced to phase II trials, concentrating on treatment-naïve PNH patients through a multi-dose regimen. The ongoing Phase II Clinical Trial demonstrates a biweekly multidose regimen in PNH patients that is safe and well-tolerated. To date, six treatment-naïve PNH patients have been administered doses with promising results. Initial findings from the ongoing Phase II Trial suggest that Ruxoprubart shows potential in enlarging PNH clone size and diminishing the necessity for pRBC transfusions by hindering the Alternative Pathway. Both the classical pathway and lipid profiles in the ongoing clinical trial appear to be within normal ranges. The trial aims to enroll a total of 12 treatment-naïve PNH patients, further advancing our comprehension of Ruxoprubart’s potential in complement-mediated diseases.

Notably, the Anti-Bb molecule marks a pioneering biologic undergoing testing in treatment-naïve PNH patients. FDA has also approved the initiation of Phase II trials for multiple indications, including C3 Glomerulopathy (C3G) and Atypical Hemolytic Uremic Syndrome (aHUS), with trials scheduled in the United States. Overseas approvals cover trials for PNH within the adult population and aHUS, extending to a pediatric population.

ABOUT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) −−−

The dysregulation of the Alternative Pathway (AP) is widely recognized as a pivotal factor influencing the course of PNH. Classified as an orphan disease, PNH presents limited and imperfect treatment options. Current sanctioned treatments either hinder infection clearance or induce hyperlipidemia. PNH is characterized by low PNH-RBC clone size, hemolysis, hemoglobinuria, low hemoglobin levels, elevated LDH, and numerous other symptoms that can lead to premature death if left untreated. Chronic symptoms and multiple organ damage are also prevalent in PNH patients.

While FDA-approved anti-C3, C5, and Factor B drugs exist for PNH treatment with potential symptom management, they are not without significant side effects. The imperative for additional treatment options for PNH, both effective and well-tolerated, remains recognized, with the potential to improve the disease outcome.

ABOUT NOVELMED −−−

NovelMed is dedicated to pioneering novel biologics for diverse complement-mediated diseases. As the first to conceptualize and validate an anti-Bb antibody for chronic complement-mediated and complement-associated disorders, NovelMed advances its leading product candidate through clinical trials, primarily focusing on hemolytic and renal disorders.

“Rooted in a commitment to creativity and compassion, NovelMed aims to deliver transformative therapies reshaping the treatment landscape for patients,” says Mr. Robert Bard, VP of Regulatory Affairs. Positioned as a leader in developing Alternative Pathway (AP)-targeted therapies, NovelMed is dedicated to tackling debilitating diseases in hematology, ophthalmology, nephrology, dermatology, and neurology.

SEEKING PARTNERSHIP TO ADVANCE THE DEVELOPMENT OF RUXOPRUBART FOR RARE DISEASES −−−

PNH, a hemolytic disorder resulting in a low PNH-RBC clone size, increased RBC transfusions, elevated LDH values, and decreased hemoglobin values, remains an orphan disease with limited treatment options. NovelMed is actively seeking licensing, investment, partnership, and acquisition opportunities to propel Ruxoprubart through further development and approval across multiple rare disease indications in various countries. For additional information, please visit www.NovelMed.com.

Robert Bard
BD Team
[email protected]

USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases

You just read:

News Provided By

January 08, 2024, 13:30 GMT


EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content.
As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™,
tries to define some of the boundaries that are reasonable in today’s world. Please see our
Editorial Guidelines
for more information.

Article originally published on www.einpresswire.com as USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases

Business

Post navigation

Previous Post: Canopus Infosystems Sets the Standard by Offering Next-Gen Healthcare Data Management
Next Post: War Day 582: Putin is Paying for His Winter Campaign

Related Posts

  • Source Intelligence Launches Accredited Online Learning Platform for Clients, Suppliers
    Source Intelligence Launches Accredited Online Learning Platform for Clients, Suppliers Business
  • Vilcek Foundation Awards 0,000 Prize in Biomedical Science to Alejandro Sánchez Alvarado
    Vilcek Foundation Awards $100,000 Prize in Biomedical Science to Alejandro Sánchez Alvarado Business
  • Ramos Tree Services Celebrates a Decade of Growth, Increasing Revenue by 40% with Exclusive Leads from Tree Leads Today
    Ramos Tree Services Celebrates a Decade of Growth, Increasing Revenue by 40% with Exclusive Leads from Tree Leads Today Business
  • 31 ADHD Stories in 31 Days with Award-Winning Journalist and TV/Radio Personality Lindsay Guentzel and ADHD Online
    31 ADHD Stories in 31 Days with Award-Winning Journalist and TV/Radio Personality Lindsay Guentzel and ADHD Online Business
  • Augmenta AgTech and Torgerson’s LLC Announce Their Partnership
    Augmenta AgTech and Torgerson’s LLC Announce Their Partnership Business
  • “Transitioning Furniture Business Online” – Omnichannel Specialists YRC Explain Why
    “Transitioning Furniture Business Online” – Omnichannel Specialists YRC Explain Why Business
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
« Jun    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Heritage Field Airport (KPTW) Celebrates Final Approval for Transformative Corporate Hangar DevelopmentJuly 25, 2025
  • Real Pro Auto Service Recognized as a CARFAX Car Care Service CenterJuly 25, 2025
  • Protein Intake and Resistance Exercise Show Great Promise for Muscle Growth and Improved Health Across All AgesJuly 24, 2025
  • The Nu-Age Group Expands its AI Driven CyberSecurity Portfolio Delivering ExcellenceJuly 24, 2025
  • Warriors Heart announces Freedom from Addiction Celebration in sync with Independence Day and MonthJuly 23, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Thriving Trends in the Global Gambling Market
    Thriving Trends in the Global Gambling Market World News
  • Who Is Mr.Putin – Putinism v02: Roman Tsepov – Grey Cardinal
    Who Is Mr.Putin – Putinism v02: Roman Tsepov – Grey Cardinal World News
  • Students Shine with Innovative Solutions at Newsmatics’ Inaugural Hackathon; Winning Team Takes Home 25,000 CZK
    Students Shine with Innovative Solutions at Newsmatics’ Inaugural Hackathon; Winning Team Takes Home 25,000 CZK Aviation
  • Reality TV better be ready for Debbie Wingham
    Reality TV better be ready for Debbie Wingham Tech
  • Christopher Bennett to Lead C4 Consulting’s (Behavioral Health Consulting) National Business Development
    Christopher Bennett to Lead C4 Consulting’s (Behavioral Health Consulting) National Business Development Business
  • Augmenta acquired by CNH Industrial
    Augmenta acquired by CNH Industrial Business
  • War in Ukraine. Analytics. Day 700 pt2: What Will Convince Ukraine to Grow Up on the 700th Day?
    War in Ukraine. Analytics. Day 700 pt2: What Will Convince Ukraine to Grow Up on the 700th Day? World News
  • War Day 678, pt2: Ukrainian Stubbornness vs. Russian Long Will
    War Day 678, pt2: Ukrainian Stubbornness vs. Russian Long Will World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .